Stay updated with breaking news from David Coman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE ...
RALEIGH - Science 37, a clinical research organization with dual headquarters in Raleigh and Los Angeles, is set to become a publicly traded company after its
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Photo by Geber86/Getty Images Science 37, a decentralized clinical trial operating system developer, has shared it's going public through a merger with special purpose acquisition company LifeSci Acquisition II Corp. Upon completion of the deal, which is expected to close in the third quarter of 2021, the combined company will operate as Science 37 and will trade on the NASDAQ under the ticker symbol “SNCE.” Science 37 will have an initial enterprise value of approximately $1.05 billion. The deal will provide the combined company with approximately $280 million in gross proceeds to supp...
Science 37, Inc., the Los Angeles, CA-based developer of the Decentralized Clinical Trial Operating System™, and LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors, entered into a definitive business combination agreement. Upon closing of the proposed transaction, the combined company will operate as Science 37 and is expected to be listed on the NASDAQ under the ticker symbol “SNCE”. The proposed transaction values Science 37 at an initial enterprise value of approximately $1.0...